Teva (Seite 81)
eröffnet am 30.01.05 10:31:56 von
neuester Beitrag 28.04.24 12:01:03 von
neuester Beitrag 28.04.24 12:01:03 von
Beiträge: 5.546
ID: 948.841
ID: 948.841
Aufrufe heute: 1
Gesamt: 705.712
Gesamt: 705.712
Aktive User: 0
ISIN: US8816242098 · WKN: 883035 · Symbol: TEVA
13,980
USD
-0,50 %
-0,070 USD
Letzter Kurs 02:04:00 NYSE
Neuigkeiten
30.04.24 · Business Wire (engl.)  |
16.04.24 · Business Wire (engl.) |
16.04.24 · Business Wire (engl.) |
11.04.24 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 1,1514 | +30,84 | |
| 1,7700 | +26,43 | |
| 0,9150 | +21,84 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 36,70 | -22,87 | |
| 15,760 | -22,93 | |
| 2,5500 | -25,22 | |
| 1,3500 | -26,63 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Ob Griever wohl ne Meinung zu den Zahlen hat und diese mit uns teilen möchte?!
Die aktie bzw. das Unternehmen sendet eigentlich positive Signale z. B. entschuldung schreitet voran, Kooperation bewerte ich positiv etc etc.
Doch die performance ist sch..der markt sieht es nicht oder will es nicht sehen. Man kann dies auch in den kommentaren auf seeking alpha sehen. Immer negativ. Wann endet dies?
Doch die performance ist sch..der markt sieht es nicht oder will es nicht sehen. Man kann dies auch in den kommentaren auf seeking alpha sehen. Immer negativ. Wann endet dies?
Antwort auf Beitrag Nr.: 64.654.996 von Einkaeufer am 05.08.20 15:19:08
super, danke !
Zitat von Einkaeufer: TEVA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
• Revenues of $3.9 billion
• GAAP diluted EPS of $0.13
• Non-GAAP diluted EPS of $0.55
• Free cash flow of $582 million
• Full year 2020 business outlook reaffirmed:
o Net revenues of $16.6 - $17 billion
o EBITDA of $4.5 - $4.9 billion
o EPS of $2.30 - $2.55
o Free cash flow of $1.8 - $2.2 billion
super, danke !
Die Teva Ergebnisse zeigen, dass der Turn-around weiter gut voranschreitet. Weitere Reduktion der Netto-Verschuldung, Margen trotz COVID relativ stabil. Mit 2.40 USD EPS für 2020 und selbst mit einem konservativen Kurs-Gewinn-Verhältnis von 10 liegt der faire Wert bei 24 USD pro Aktie - also 90% über aktuellem Kurs. Da sind noch viele potentielle Risiken eingepreist.
TEVA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
• Revenues of $3.9 billion
• GAAP diluted EPS of $0.13
• Non-GAAP diluted EPS of $0.55
• Free cash flow of $582 million
• Full year 2020 business outlook reaffirmed:
o Net revenues of $16.6 - $17 billion
o EBITDA of $4.5 - $4.9 billion
o EPS of $2.30 - $2.55
o Free cash flow of $1.8 - $2.2 billion
• Revenues of $3.9 billion
• GAAP diluted EPS of $0.13
• Non-GAAP diluted EPS of $0.55
• Free cash flow of $582 million
• Full year 2020 business outlook reaffirmed:
o Net revenues of $16.6 - $17 billion
o EBITDA of $4.5 - $4.9 billion
o EPS of $2.30 - $2.55
o Free cash flow of $1.8 - $2.2 billion
Trading Spotlight
oder sind die schon draußen?
Kommen um 15 30 die Zahlen?
Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and biopharmaceutical company Alvotech today announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates. This strategic partnership combines Teva’s long-standing commercial presence and extensive infrastructure in the U.S. market with Alvotech’s scientific experience and state-of-the-art biologics manufacturing. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas.
Robert Wessman, Alvotech’s founder and Chairman said, “We are very proud to announce our strategic alliance with Teva – a leading global pharmaceutical company, to accelerate the introduction and adoption of new biosimilar medicines for patients in the U.S. market. This is not only a big moment for the biosimilar industry but also a very special moment for Alvotech, as we continue to join forces with leading global and regional partners around the world.“
“This commercial partnership with Alvotech will enable Teva to lend its technical expertise in working with the FDA to bring products to the U.S. market while broadening its growing biosimilar portfolio and continuing to leverage its unique cross-functional expertise across both specialty and generic medicines,” said Brendan O’Grady, Executive Vice President and Head of North America Commercial at Teva. “This collaboration is another step in our unwavering commitment to develop and enable access to quality medications to help improve the lives of patients."
Under this partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S. The originator products of these five candidates currently generate around $35 billion in U.S. sales. The agreement includes an upfront payment, with subsequent milestone payments over the next several years. Teva and Alvotech will share profit from the commercialization of the biosimilars. All other financial terms and product details remain confidential.
Robert Wessman, Alvotech’s founder and Chairman said, “We are very proud to announce our strategic alliance with Teva – a leading global pharmaceutical company, to accelerate the introduction and adoption of new biosimilar medicines for patients in the U.S. market. This is not only a big moment for the biosimilar industry but also a very special moment for Alvotech, as we continue to join forces with leading global and regional partners around the world.“
“This commercial partnership with Alvotech will enable Teva to lend its technical expertise in working with the FDA to bring products to the U.S. market while broadening its growing biosimilar portfolio and continuing to leverage its unique cross-functional expertise across both specialty and generic medicines,” said Brendan O’Grady, Executive Vice President and Head of North America Commercial at Teva. “This collaboration is another step in our unwavering commitment to develop and enable access to quality medications to help improve the lives of patients."
Under this partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S. The originator products of these five candidates currently generate around $35 billion in U.S. sales. The agreement includes an upfront payment, with subsequent milestone payments over the next several years. Teva and Alvotech will share profit from the commercialization of the biosimilars. All other financial terms and product details remain confidential.
Teva Pharmaceutical Q2 2020 Earnings Preview
Aug. 4, 2020 11:59 AM ET|About: Teva Pharmaceutical Ind... (TEVA)|By: Mohit Manghnani, SA News Editor
•Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q2 earnings results on Wednesday, August 5th, before market open.
•The consensus EPS Estimate is $0.53 (-11.7% Y/Y) and the consensus Revenue Estimate is $3.94B (-9.2% Y/Y).
•Analysts expect Non-GAAP gross margin of 51.5% and Non-GAAP operating margin of 23.8%.
•Over the last 2 years, TEVA has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time.
•Over the last 3 months, EPS estimates have seen 2 upward revisions and 14 downward. Revenue estimates have seen 2 upward revisions and 11 downward.
Aug. 4, 2020 11:59 AM ET|About: Teva Pharmaceutical Ind... (TEVA)|By: Mohit Manghnani, SA News Editor
•Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q2 earnings results on Wednesday, August 5th, before market open.
•The consensus EPS Estimate is $0.53 (-11.7% Y/Y) and the consensus Revenue Estimate is $3.94B (-9.2% Y/Y).
•Analysts expect Non-GAAP gross margin of 51.5% and Non-GAAP operating margin of 23.8%.
•Over the last 2 years, TEVA has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time.
•Over the last 3 months, EPS estimates have seen 2 upward revisions and 14 downward. Revenue estimates have seen 2 upward revisions and 11 downward.
Antwort auf Beitrag Nr.: 64.633.270 von mediacool am 03.08.20 19:49:52
Q2 2020 Teva Pharmaceutical Industries Ltd. Earnings Conference Call
August 05, 2020 08:00 AM
Ich schätze :
- Umsatz leicht gesteigert (Wegen Covid)
- Verschuldung weiter zurückgeführt (Net Debt von 24,3 Mrd.US$ auf 23,8 Mrd. US $)
- Im Juli - wurde auch eine Anleihe fällig, die bedient wurde July 2016-Euro 0,375 % --1.886 Jul 20 July 2020
aber evtl. weitere Abschreibungen, vor dem Hintergrund zahlreicher Klagen
-
Wieso Donnerstag ? - Mittwoch!
Zitat von mediacool: Heute mal etwas mehr dynamik im bau. Vielleicht ein vorbote des ergebnisses am Donnerstag.
Q2 2020 Teva Pharmaceutical Industries Ltd. Earnings Conference Call
August 05, 2020 08:00 AM
Ich schätze :
- Umsatz leicht gesteigert (Wegen Covid)
- Verschuldung weiter zurückgeführt (Net Debt von 24,3 Mrd.US$ auf 23,8 Mrd. US $)
- Im Juli - wurde auch eine Anleihe fällig, die bedient wurde July 2016-Euro 0,375 % --1.886 Jul 20 July 2020
aber evtl. weitere Abschreibungen, vor dem Hintergrund zahlreicher Klagen
-
Durchsuchen
| Zeit | Titel |
|---|---|
| 24.07.23 |